The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
As at 30 November 2022, having recently received the R&D tax credit for FY 2022, the Company has cash of £10.0 million, and through deferring certain expenditure on proprietary programmes and other longer term development plans, the cash runway will be extended until at least the start of the fourth calendar quarter of 2023. This is not expected to compromise the Company's ability to sign commercial exosome collaborations which upon completion should extend the runway until at least 2024.
Notice there selling down, at one time they had a director on board, helped them with finance,
What is real sad is that just like a lot of these plays, its only when they are right up against it they start taking cash burn more seriously and look at costs. The previous results albeit horrendous cash burn did show improvements.
The previous funding boom for biotech's on balance hasn't helped investors one jot IMO, money has come far too easy to some of these businesses and they just haven't valued it, just spent money without regard because well they can. Then they end up in dire trouble because they are stuck with previous spending commitments and now we are in a prolonged funding drought there are few places to turn.
Interested to see what the results come out like. I suspect there will be improvements but with the commitments and high pay roll how can you address that? the BOD will be feeling the heat now for sure. Hope they can pull something out the hat for sure.
Presentation on Investor meet company on the 25th, good luck.
Actions need urgently there needs to be a breakthrough pronto or this share will go down the sewer to much red tape a positive anousment to the media would HELP, ADVERTISE There must be some glimmer of hope.
Cash will be dwindling by the day, much like the SP
Valued at 3.86m now. Way under cash! Crazy
No matter what happens and which ever way you cut it I’ve lost my shirt on Rene. So an historical lens is now a nonsensical and an unproductive way to look at this share. The fact I’ve had it for over a decade is meaningless. As Dibs suggests however does the present eight cents provide an opportunity whilst there’s still life to make 40 or even 100% on the price? It may well do (or maybe it won’t) but good luck to those taking that chance. At least it won’t take years for you to know the outcome of your bet.
Cash getting eaten into not much value will be put on that.
The two 20k trades just printed look like sells but they are both buys by me.
Happy to be buying at a valuation of £4.7m which is substantially less than cash in bank!
Had great promise nice write up in the papers then and here we are still . IMO pharma are back as its been crushed so much .
Like the 100 to one shot at Belmont, still on the track and maybe even worth something as horse meat but sadly it doesn’t mean it’ll win. But my dollar landed on its nose over a decade ago so will watch the race until the end, even if I wont hold my breath. But good luck to all still betting.
Currently less than a £5 million market cap. My take is that the sum value of this business has to be more than £5m which is a pittance.
So for me this is a buy at this level. They are funded into next year. Indeed the company is valued at less than its cash in bank!
When, will Rene shareholders get a divi I have only been waiting twenty years!
Todays Guardian has a review of ‘Cancer and Heart disease vaccines ready by end of the decade….’ If only this article gave indication it was made possible by use of ReNeuron Exosomes … see https://www.theguardian.com/society/2023/apr/07/cancer-and-heart-disease-vaccines-ready-by-end-of-the-decade?CMP=Share_iOSApp_Other
I guess the recent Board purchases are designed to try to demonstrate confidence but as Waccy highlights, the latest probably represents about a month’s remuneration from her NED role at Rene. Perhaps more sadly, unless London’s governance standards are slipping, it’s a bad look if these purchases are closely followed by positive news’ flows. So we may have a while longer to wait! Nonetheless for those who celebrate it, have a great Easter.
She just bought £4k of shares. Basically nothing.
Barbara Staehelin just increased her shareholding as well so would seem a definite show of confidence in company and worth. Wonder how many more purchases we may see and if purchases cease if that will then indicate imminent good news?
If he’s got so much money he doesn’t NEED to punt.
Peanuts money 4 Ross that's no show of confidence more a punt,
New Co plenty of promises but No concrete actions, better get a move on hope he has plenty of money to back Rene because I am broke and so are anybody that pursued this share!
This share needs some positive new Now or it will sink faster then the Titanic, to much red tape there must be some sort of brake through they need to advertise my believe is sadly going down.
Iain Ross added a further 100k shares this morning. He clearly sees value and foresees better outcomes.
Looking at the financial position the current MC IS £5.25 million.
I estimate the current cash position is circa £7.5 million.
This is based on the following calculations :
Cash @ 30.9.22 was £10.5 million
Prev 6 month period loss £3.2m
Estimated current 6 month loss circa £3m (should be a little less given cost savings)
£10.5m less £3m = £7.5m
Therefore this is currently discounted under cash by some £2m +
All current assets in for free
On that basis, at this price, this has go to be worth a punt given cash runway now extends into next year.
Iain has done what he said, bought 400k in total now. Lets hope he is true to his word when he says we going to sign deals this year.
Ian Ross just purchased another 100k shares,now has 0.7% holding. I guess the view internally is very good re cash burn and prospects.Directors steadily making share purchases.I can only assume that they are very confident of something happening in next 12 months and as they have the experience of the industry and these situations I hope they confidence is well founded.
I've no idea, unfortunately. I just hope Reneuron can get through the current biotech bloodbath.